A Houston vet has seen growth in business for her mobile vet company due to the pandemic. Now, she's planning major growth. Photo courtesy of Rollin' Vets

It's safe to say that the real winners of work-from-home trends that sparked due to the pandemic are our pets. Dogs and cats that were used to not seeing their owners for eight hours every work day now have 24-hour access to attention, treats, and ear scratches.

This increased attention pets are getting from their owners has also meant an increased awareness of pet health, says Katie Eick, founder of Houston-based Rollin' Vets, a startup that has mobilized veterinary services.

"People are home and observing their animals more. They're seeing and recognizing things they might not have if they were at work all day," Eick says.

Each of the four mobile units can do most everything a brick-and-mortar clinic can. Photo courtesy of Rollin' Vets

That's, of course, not the only way the pandemic has affected business for Eick. She founded her company in 2016 and was seeing steady growth as delivery and on-demand services like Uber, DoorDash, etc. increased in use and awareness.

"We were continuously growing slowly — then COVID hit. It really cemented that … all the convenience services are in the forefront of people's minds." Eick tells InnovationMap. "COVID made it clear that this was a necessary service."

Like a lot of businesses, vet clinics closed to the public and only accept drop-off patients. This new way of seeing pets coupled with the fact that most people are working remotely from home also played to the advantage Rollin' Vets — why drive your pet to drop off at a clinic when the vet can come to your driveway?

COVID-19 closures and social distancing practices also called for a rise in veterinary telemedicine — something that Eick says has been challenging for her to utilize both due to the board of medicine having strict regulations in place as well as the challenges trying to provide virtual animal care poses.

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

"Humans can get on and tell you their symptoms, where they hurt, and how they are feeling. Animals can't do that," Eick says.

Earlier in the pandemic, she did provide some telemedicine visits. The board, which bans telemedicine care for pets not previously seen by a vet or pets that haven't been seen in over a year, loosened the regulations to allow for virtual care of pets if the vet has ever seen the animal. This was helpful for providing refill medications, for instance.

Then, Eick had an appointment with a four-year-old French bulldog that changed her mindset on telemedicine. The dog had some stomach issues when his owner made an appointment with Eick. By the time she got to the dog, he had more or less seemed fine — he was eating again and didn't seem despondent in any way. But when Eick performed his exam, she found a mass.

"If I would have just looked at that dog over a video chat, he would have died," Eick says, adding that she got the dog right into surgery at a nearby facility.

In this case, telemedicine wouldn't have provided a solution for the animal, but Eick hasn't ruled virtual care out in general.

"I do think there's place for it, but we have to be really careful," she says.

At this point, Eick has more than proven her value proposition for her company. She has four mobile units with a team of four vets, six technicians, and four receptionists. As far as funding goes, she's pitched to the Houston Angel Network and is looking for angel investors. She's also planning on looking into crowdfunding as an option.

She's planning for growth — starting with Dallas and San Antonio — and sees the company adopting a franchise model that will eventually take Rollin' Vets out of state.

"We're aiming to be a nationwide brand," Eick says.

Rollin' Vets is planning to fundraise on NextSeed next month. Photo courtesy of Rollin' Vets

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Houston-based veterinary biotech startup modernizes cancer treatments for dogs

Paw-dern medicine

More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies recently accomplished a significant milestone. In October, CAVU's specialized immunotherapy was administered to its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals."

At CAVU, O'Connor dedicates her time to modernizing cancer care for dogs by developing an Autologous Prescription Product, otherwise known as adoptive T-cell therapy for dogs. The T-cell therapy is currently offered as a companion treatment to other canine cancer treatments, such as chemotherapy, radiation or surgery, O'Connor said.

Historically, cancer research for animals has lagged behind that of humans, and cancer diagnoses have come late due to the language barrier, O'Connor said. Of the dogs who enter remission, a majority of them relapse within 10 months to one year, she said.

"A majority [of dogs] are diagnosed at stage four, and you have to become very aggressive," O'Connor said. "For B-cell lymphoma, with the current treatments right now and the current standard of [therapies], less than 20 percent make it to two years post-diagnosis."

Launching CAVU
O'Connor first began studying T-cell therapy for humans with cancer during her post-doctoral fellowship at M.D. Anderson Cancer Center. Her fellowship also partnered with Texas A&M University's Small Animal Hospital to develop a clinical trial studying the effects of adoptive T-cell therapies on dogs with B-cell lymphoma.

T-cell therapy is a cellular-based treatment in which a type of white blood cells — or the cells that fight off tumors and infections — are harvested from blood samples drawn from patients. The cells are then injected back into the patient through an IV to fight the cancerous cells, O'Connor said.

Unexpectedly, O'Connor's 19-year-old dog, Bubbles, was diagnosed with transitional cell carcinoma in 2008 and later dying from it in December 2009. Five years later, O'Connor's sister's 6-year-old dog, Daisy, also died from transitional cell carcinoma. O'Connor said she remembers feeling helpless as she watched the dogs succumb to the disease.

"I was giving them drugs and protocols that were from 1980 … and I was really upset that there wasn't much more we could do for our dogs — especially because I treat my dogs like family," O'Connor said.

That was when O'Connor realized she wanted to help prevent other people from feeling the pain of losing their furry family members. While T-cell therapy is not a new method of treating cancer in humans, O'Connor focused on modifying the serum to create a treatment plan appropriate for dogs.

However, launching a company focusing specifically on treating cancer in animals was not without its challenges; O'Connor said she had to learn how to start a business, make industry connections, and adopt an entrepreneurial mindset.

To help with this, CAVU also connected with various entrepreneurial accelerators, such as Houston Technology Center and Station Houston, which are associations that help place young businesses in front of investors.

CAVU later became a member of the Houston Angel Network — a group of private investors of high net worth individuals that as a group invest in startups. By presenting her business to HAN and its investors, CAVU was able to gain financial backing.

CAVU also recently joined the Capital Factory in early 2018, an Austin-based accelerator program for entrepreneurs in Texas. O'Connor said the program has helped her meet investors, mentors and other startups.

"The way I overcame a lot of this [the early challenges] is by education, listening and trying to navigate and talk with as many of the right people as I could that had experience," she said.

The future of CAVU
Since CAVU treated its first patient in October, CAVU's adoptive T-cell therapy treatment has been administered to six dogs, O'Connor said. CAVU's T-cell therapy is currently available at more than 12 veterinary clinics across the country, including clinics in Texas, Florida, Pennsylvania, New York, North Carolina, and Missouri.

Additionally, four Houston-area clinics currently offer the T-cell therapy treatment: Garden Oaks Veterinary Clinic, Bayou City Veterinary Hospital, Memorial-610 Hospital for Animals, and Sugar Land Veterinary Specialists.

In order for a dog to be considered as a candidate — though it is ultimately up to the veterinarian on whether the T-cell therapy is right for specific dogs — the dogs must weigh more than 8 pounds, not be allergic to mouse or cow products and have no active autoimmune diseases.

The company also launched a new clinical trial with A&M University in October, looking at the effects of CAVU's T-cell therapy coupled with reduced chemotherapy periods for dogs, from roughly 19 to 26 weeks of chemotherapy to 6 to 8 weeks.

While CAVU's therapy is currently only available for dogs, O'Connor said her team plans to modify the T-cell therapy to be administered in other animals.

"We have a lot of cat owners ask us [about treatment] and we are going to do that for the next round in funding," she said. "We're going to look at how to translate this for cats and eventually horses."

O'Connor said that CAVU will launch more clinical trials with A&M University's Small Animal Hospital in the future, with CAVU aiming to make T-cell therapy treatments for cats and horses available in 2020.

Looking back, O'Connor said she has come a long way in her career path: from working with sea animals at the Newport Aquarium in Kentucky to studying human immunology and toxicology, but she's returned to studying animals.

"It's amazing how I pivoted, but at the end of the day I kind of came back to animals … and I came back full circle in a way I could have never expected," she said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH expands Medical Center footprint with $77M research facility

breaking ground

The University of Houston broke ground on a brand new $77.5 million Medical Research Building last week that will host clinical trials and a virtual reality behavioral health suite, among other laboratories. Designed by SmithGroup, it will be the second building on the UH Medical Center campus after the Fertitta College of Medicine opened in 2022.

“The Medical Research Building was designed to foster collaboration and discovery while creating a welcoming environment for students, researchers and the community,” Kalman Nagy, higher education studio design leader for SmithGroup, said in a news release. “As the second building on the University of Houston’s medical campus, we wanted to create a strong connection to the College of Medicine and the surrounding woodlands, with outdoor terraces, shared learning spaces and natural views that inspire interaction and innovation.”

Located just behind the Fertitta building at 5150 Medical Service Drive, the 57,000-square-foot building will house wet laboratories, computational research spaces and specialized facilities for clinical research. The virtual reality behavioral health suite will use immersive technology to deliver care through manufactured audio and visual environments. It’s part of the college’s vision for developing new medical advancements in the heart of Houston’s medical community. The groundbreaking comes on the heels of the launch of the university's cross-disciplinary academic venture, UH Health, this summer.

“This groundbreaking marks an important next step in the growth of the Fertitta College of Medicine and UH Health,” Dr. Jonathan McCullers, vice president for health affairs at UH, added in the release. “We are building the research capacity to match our ambitions—bringing together scientists, physicians and experts from across the University to accelerate discovery and turn promising ideas into solutions that improve people’s lives.”

UH’s journey to establish a significant presence alongside the University of Texas and Baylor in the Medical Center started in 2009 when it became an official full institutional member. The university launched its plans for the Fertitta building in 2013, and is pursuing Health Science Center designation from the Texas Legislature in the next year’s session.

“The research that will take place here will directly benefit our community,” UH President Renu Khator added. “Diseases do not recognize disciplinary silos, and neither should our research. This building will bring together experts from across UH to break down those barriers, work across disciplines and tackle some of our most complex health challenges.”

The building is slated to open in 2028.

Houston ranks among 15 U.S. hot spots for women in tech

Ranking It

Houston is soaring among the best places in the U.S. for women in tech, a new report says. Houston ranked No. 15 nationwide in SmartAsset's new report, "Best and Worst Cities for Women in Tech — 2026 Study," which compared the 50 biggest U.S. cities across four metrics:

  • Gender pay gap — women's median earnings as a percentage of men’s median earnings in tech
  • The share of all tech workers that are women
  • The overall concentration of employment for tech workers, defined as "tech workers as a share of the local workforce"
  • Women tech workers’ median earnings, adjusted for regional price parity
For the purpose of the study, tech workers are defined as "city residents employed in computer and mathematical occupations." The study's findings show that fewer than 9,500 tech workers in Houston are women, or 25.6 percent of the total tech workforce in the city. In total, tech workers in general make up less than 3 percent of the Houston workforce.Despite the high ranking, women tech workers in Houston have a sizeable gap to cross to receive equal pay compared to their male counterparts in the same industry. Women tech workers make just over $97,000 in median earnings after adjusting for regional price parity, which is only 93 percent of what male tech workers make, SmartAsset found.

There are only two U.S. cities where women in tech earn more than what their male counterparts: Miami and Memphis, Tennessee. Women tech workers in Miami make an adjusted $88,650 in median earnings, or 101.7 percent of what men in tech make. In Memphis, women make $84,718 in adjusted earnings, or 101.5 percent of what men in tech earn.

The findings also assert that women remain underrepresented in the nation's overall tech sector, despite making up nearly half of the total workforce. Only 22.6 percent of the country's tech labor force is made up of women, according to the Equal Employment Opportunity Commission."Opportunities for women in tech can vary considerably by location, and these differences shape access to jobs, career advancement and earning potential," the report's author wrote. "In some places, women account for a larger share of tech workers, face narrower pay gaps and enjoy a stronger local labor market. In others, they may encounter a more challenging career environmentThe six other Texas cities that earned spots in the report are Austin (No. 6), Fort Worth (No. 26), Dallas (No. 32), Arlington (No. 38), San Antonio (No. 42), and El Paso (No. 49).

The top 10 best U.S. cities for women in tech are:

  • No. 1 – San Jose, California
  • No. 2 – Seattle, Washington
  • No. 3 – San Francisco, California
  • No. 4 – Atlanta, Georgia
  • No. 5 – Baltimore, Maryland
  • No. 6 – Austin, Texas
  • No. 7 – Oakland, California
  • No. 8 – Portland, Oregon
  • No. 9 – Boston, Massachusetts
  • No. 10 – Minneapolis, Minnesota
---

This article first appeared on CultureMap.com.